IDH-mutant and 1p/19q-codeleted oligodendroglioma
MONDO:0859592An anaplastic oligodendroglioma that has material basis in IDH gene family mutation and combined whole-arm losses of 1p and 19q (1p/19q codeletion).
2831 clinical trials for this condition and its sub-types, 9 tagged with IDH-mutant and 1p/19q-codeleted oligodendroglioma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of IDH-mutant and 1p/19q-codeleted oligodendroglioma
-
New hope for brain tumor patients: targeted drug shows promise in phase 3 trial
Disease control Recruiting nowThis study tests a drug called safusidenib in people with a type of brain tumor (glioma) that has a specific gene mutation (IDH1). The trial has three parts: one for recurrent tumors, one for high-risk tumors after standard treatment, and one for a specific tumor type after surge…
Phase 3 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New cell therapy trial hopes to tackle recurrent brain cancer
Disease control Recruiting nowThis early-stage trial is testing a personalized cell therapy for adults with recurrent oligodendroglioma, a type of brain tumor. The treatment involves taking a patient's own immune cells and stem cells, modifying them in the lab, and giving them back to fight the tumor. The mai…
Phase 1 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC